青蒿琥酯抑制Twist1蛋白表达和血管再生以及降低口腔鳞癌细胞Tca8113转移的作用

目的 研究青蒿琥酯抑制Twist 1表达、降低口腔鳞癌细胞的转移及对血管生成的抑制作用.方法 采用50、100、150、200 μg·mL-1的青蒿琥酯体外培养的口腔鳞癌细胞,然后分别采用Western blot法、MTT法、划痕实验及流式细胞仪检测不同浓度的青蒿琥酯干预对口腔鳞癌细胞Twist1表达、增殖、迁移及凋亡的影响;采用鸡胚尿囊膜检测青蒿琥酯对鸡胚尿囊膜血管生成的影响.结果 与对照组对比,青蒿琥酯可抑制Twist1蛋白的表达、口腔鳞癌细胞的增殖和迁移,且存在时间和剂量依赖性;青蒿琥酯可引起细胞的凋亡,处理组的细胞凋亡率显著高于对照组;青蒿琥酯对鸡胚尿囊膜血管新生有一定的抑制作用(P＜0.05).结论 中药青蒿琥酯可抑制Twist 1蛋白的表达、细胞增殖、迁移,同时可有效抑制血管再生.     

血瘤散抑制肿瘤血管生成的实验研究

目的 观察中药复方血瘤散对血管生成的抑制作用。方法 中药复方血瘤散煎制成汤剂,灌至胃大鼠,数次灌胃后取血清。Hanks液稀释血清后作测试物,观察对鸡胚尿囊膜血管生成的影响;制备含药血清培养基,观察含药血清培养基对人脐静脉血管内皮细胞增殖、凋亡、迁移的影响。结果 复方血瘤散对鸡胚绒毛尿囊膜血管生成及血管内皮细胞的迁移有一定抑制作用,但对血管内皮细胞的形态、增殖、凋亡没有明显影响。结论 血瘤散有一定抑制血管生成作用。     

整合素阻断多肽HM-3体外抑制新生血管的研究

研究整合素阻断多肽HM-3体外对血管生成的作用。应用鸡胚尿囊膜实验、大鼠动脉环实验及Matrigel实验考察整合素阻断多肽HM-3抗血管生成作用。结果:鸡胚尿囊膜实验和大鼠动脉环实验表明HM-3能够抑制体外血管生成,多肽HM-3 0.05μg对鸡胚尿囊膜新生血管生成的抑制作用最强,多肽HM-3 8μg/mL对大鼠动脉环微血管生成抑制作用最强。Matrigel实验表明HM-3 7～8μg/mL对内皮细胞生长因子添加剂(ECGS)诱导的HUVEC细胞体外分化成管状结构抑制作用最强。整合素阻断多肽HM-3具有显著的体外抗血管生成的作用。     

青蒿琥酯对人卵巢癌细胞诱导血管新生的抑制效应

目的探讨青蒿琥酯（ART）对人卵巢癌CAOV3细胞诱导血管新生的影响及其机制。方法培养人卵巢癌细胞株（CAOV3）,采用主动脉环体外培养和鸡胚绒毛尿囊膜体内血管生长实验观察ART对人卵巢癌CAOV3细胞诱导血管新生的影响。采用酶联免疫吸附法检测ART对人卵巢癌CAOV3细胞分泌血管内皮生长因子（VEGF）的影响。结果主动脉环体外培养和鸡胚绒毛尿囊膜体内血管生长实验结果显示,ART浓度为3μmol/L时即可明显减少CAOV3细胞诱导的血管生成（P〈0.01）。酶联免疫吸附法（ELISA）检测结果显示,ART浓度在3μmol/L时即可明显减少CAOV3细胞分泌VEGF（P〈0.05）。结论 ART具有抑制卵巢癌CAOV3细胞诱导血管新生的作用;其作用机制与ART抑制卵巢癌CAOV3细胞分泌VEGF有关。     

鬼箭羽提取物抑制血管生成的实验研究

目的 研究鬼箭羽氯仿提取物对血管生成的影响.方法 采用人脐静脉内皮细胞模型（HUVEC）、大鼠动脉环模型（rat aortic rings）和鸡胚绒毛尿囊膜（CAM）模型研究鬼箭羽提取物抑制血管生成作用.结果 8μg·mL-1鬼箭羽提取物显著抑制人脐静脉内皮细胞的增殖,抑制率达到36.2%;2μg·mL-1和4μg·mL-1鬼箭羽提取物能够显著抑制大鼠动脉环新血管结构形成,抑制率分别达到56.41%和65.25%;鬼箭羽提取物20 μg·个-1与40μg·个-1.对鸡胚绒毛尿囊膜（CAM）血管抑制率分别达到了22.6%与31.2%.结论 鬼箭羽提取物具有显著的抗血管生成活性.     

多肽AP25抗肿瘤活性研究

目的 研究多肽AP25在组织水平和整体动物水平的抗肿瘤作用,为临床试验提供依据.方法 采用大鼠动脉环和鸡胚尿囊膜实验检测AP25对血管新生的抑制作用,采用动物体内实验评价AP25抗肿瘤活性.结果 大鼠动脉环实验表明多肽AP25可以抑制大鼠动脉环微血管生成,并且在0.25 mg·L-1时抑制率达到62.19%;鸡胚尿囊膜实验表明多肽AP25对血管新生有明显的抑制作用,且具有剂量依赖关系,20 mg·L-1抑制率达到80.37%;动物体内实验表明多肽AP25在裸鼠移植瘤模型上可以明显地抑制HCT116细胞的生长.结论 多肽AP25对新生血管具有明显的抑制作用,主要通过抑制新生血管达到抑制肿瘤的生长,进而发挥抗肿瘤的活性.     

广西尖吻蝮蛇毒K组分抗血管生成活性研究

目的探讨广西尖吻蝮蛇毒小分子多肽组分（K组分）对血管生成的抑制作用。方法采用噻唑蓝法检测K组分对培养的人脐静脉内皮细胞株ECV304的生长抑制情况,结晶紫法测定K组分对ECV304细胞的黏附抑制作用,鸡胚尿囊实验观察K组分对血管生成的影响。结果K组分对人脐静脉内皮细胞株ECV304的增殖有抑制作用并呈明显的时 效及量 效关系,能够抑制ECV304细胞与纤维连接蛋白的黏附和鸡胚尿囊血管生成。结论广西尖吻蝮蛇毒K组分对血管生成有抑制作用。     

地非三唑抑制血管新生作用的研究

目的从细胞、器官、整体三个水平观察地非三唑抑制血管的新生作用。方法细胞水平用MTT法测定地非三唑对人脐静脉内皮细胞的增殖抑制作用;器官水平上利用鸡胚绒毛尿囊膜(CAM)血管新生模型,观察地非三唑抑制CAM血管新生的情况;并在整体水平上采用家兔角膜血管新生模型,于缝线后第3d用地非三唑于结膜囊注射给药,每天观察角膜血管新生情况。结果地非三唑能有效抑制人脐静脉EVC304细胞的增殖,其IC50根据药物作用时间的不同,维持在9~15μg.mL-1;并能使CAM新生血管明显减少甚至消失,对家兔角膜新生血管也有同样抑制作用。结论地非三唑能抑制血管新生作用。     

新生霉素抑制血管生成及其与长春新碱的协同作用

目的研究新生霉素的抑制血管生成作用及其机制。方法以鸡胚尿囊膜模型测定对血管生成的作用，并分别用MTT法、明胶酶谱法等观察新生霉素对于内皮细胞和肺癌PG细胞的影响。结果新生霉素200 μg/egg对鸡胚尿囊膜血管生成的抑制率为68.7％，且呈浓度依赖性抑制内皮细胞的增殖、运动、MMP-2分泌以及管腔的形成；新生霉素和长春新碱对血管生成及PG细胞的增殖均有明显的协同作用。结论本研究首次确定新生霉素具有抑制血管生成活性,与长春新碱联合可增强对血管生成的抑制作用。     

地非三唑抑制血管新生作用的研究

目的从细胞、器官、整体三个水平观察地非三唑抑制血管的新生作用。方法细胞水平用MTT法测定地非三唑对人脐静脉内皮细胞的增殖抑制作用;器官水平上利用鸡胚绒毛尿囊膜(CAM)血管新生模型,观察地非三唑抑制CAM血管新生的情况;并在整体水平上采用家兔角膜血管新生模型,于缝线后第3d用地非三唑于结膜囊注射给药,每天观察角膜血管新生情况。结果地非三唑能有效抑制人脐静脉EVC304细胞的增殖,其IC50根据药物作用时间的不同,维持在9～15μg·mL^-1;并能使CAM新生血管明显减少甚至消失,对家兔角膜新生血管也有同样抑制作用。结论地非三唑能抑制血管新生作用。     

青蒿琥酯的抗血管生成作用

目的研究青蒿琥酯对血管生成的抑制作用。方法用人脐静脉内皮细胞(HUVEC)的生长、迁移及小管形成实验研究药物的体外抗血管生成作用;用人卵巢癌裸鼠移植瘤模型和免疫组化法研究药物的体内抗血管生成作用。结果青蒿琥酯浓度2.5 μmol·L^-1时,对HUVEC的增殖、迁移和小管形成均有显著的抑制作用;HUVEC 48 h的IC₅₀值为(21±3) μmol·L^-1。在整体实验中,青蒿琥酯50 mg·kg^-1·d^-1即可明显减少肿瘤的血管生成,抑制肿瘤生长;免疫组化结果表明,青蒿琥酯可以抑制VEGF和KDR/flk-1在肿瘤组织中的表达。结论青蒿琥酯有抗血管生成作用,提示该类药物在抗血管生成中有潜在的应用价值。     

芸香宁碱抑制血管生成作用的研究

目的：研究芸香宁碱对血管生成的抑制作用,并研究其初步的作用机制。方法用人脐静脉内皮细胞（HUVEC）的生长、迁移实验及体内动物模型－鸡胚绒毛尿囊膜法（CAM 法）研究化合物的体内外抗血管生成作用;用酶联免疫吸附法检测芸香宁碱在非凋亡剂量时对肿瘤细胞培养上清液中 VEGF 蛋白分泌量的影响。结果芸香宁碱对血管内皮细胞具有优先抑制作用,对 HUVEC 的半数抑制剂量为（33．2±0．4）μmol·L －1,而对其他肿瘤细胞的 IC50值均大于这一数值;芸香宁碱在体外能够明显抑制内皮细胞的迁移和对细胞外基质黏附作用,并呈剂量依赖性,体内实验显示30μmol·L －1剂量浓度时显著抑制 CAM新生血管形成;芸香宁碱在15μmol·L －1和30μmol·L －1的浓度剂量时显著抑制人肝癌 HepG2细胞培养上清液中VEGF 蛋白的分泌,具有显著性差异。结论芸香宁碱在非凋亡浓度剂量具有抑制新生血管形成作用,其机制与抑制血管内皮细胞增殖以及抑制肿瘤细胞表达 VEGF 有关。     

Inhibition of angiogenesis by blockers of volume-regulated anion channels

Osmotic cell swelling activates an outwardly rectifying Cl(-) current in endothelial cells that is mediated by volume-regulated anion channels (VRACs). In the past, we have shown that serum-induced proliferation of endothelial cells is arrested in the presence of compounds that potently block the endothelial VRACs. Here we report on the effects of four chemically distinct VRAC blockers [5-nitro-2-(3-phenylpropylamino)benzoic acid] (NPPB), mibefradil, tamoxifen, and clomiphene-on several models of experimental angiogenesis. Mibefradil (20 microM), NPPB (100 microM), tamoxifen (20 microM), and clomiphene (20 microM) inhibited tube formation by rat microvascular endothelial cells plated on matrigel by 42.9 +/- 8.8%, 25.3 +/- 10.4%, 32.2 +/- 4.5%, and 20 +/- 5.8%, respectively (p < 0.05). Additionally, NPPB (50-100 microM) and mibefradil (10-30 microM) significantly inhibited bFGF (10 ng/ml) + TNFalpha (2.5 ng/ml)-stimulated microvessel formation by human microvascular endothelial cells plated on fibrin by 30-70%. Furthermore, NPPB, mibefradil, and clomiphene concentration dependently inhibited spontaneous microvessel formation in the rat aorta-ring assay and vessel development in the chick chorioallantoic membrane assay. These results suggest that VRAC blockers are potent inhibitors of angiogenesis and thus might serve as therapeutic tools in tumor growth and other angiogenesis-dependent diseases.     

毛萼乙素抑制人正常及肝癌血管生成的作用研究

目的:研究毛萼乙素对人脐静脉内皮细胞(HUVEC)增殖的影响以及对人肝癌血管生成的影响。方法:采用改良MTT法测试6个浓度的毛萼乙素在体外对原代培养的HUVEC增殖的影响;用人肝癌鸡胚尿囊膜血管复制模型,测定毛萼乙素在器官水平对血管生成的抑制作用。结果:毛萼乙素对HUVEC增殖具有显著的抑制作用,半数抑制浓度(IC50)=7.27μg·mL-1;抑制效应呈剂量和时间依赖性。在剂量为25、50、100μg·mL-1时对人肝癌鸡胚尿囊膜血管面积比的抑制率分别为14.15%、48.72%、60.63%,抑制作用中等;其中剂量在50μg·mL-1时与阳性对照反应停相当(P>0.05)。结论:毛萼乙素对人脐静脉内皮细胞的增殖有显著的抑制作用,并能显著抑制人肝癌细胞诱导的鸡胚尿囊膜血管生成。     

Juice of eclipta prostrata inhibits cell migration in vitro and exhibits anti-angiogenic activity in vivo

BACKGROUND: The invasion of cancer cells is critical for metastasis. The effects of Eclipta prostrata, a Thai medicinal plant, on invasion, migration and adhesion of cancer cells were investigated and the anti-angiogenic activity in vivo was evaluated. MATERIALS AND METHODS: In vitro invasion and migration assays were performed in modified Boyden chambers. In vivo anti-angiogenic activity was determined using the chick chorioallantoic membrane (CAM) assay. RESULTS: E. prostrata juice inhibited cancer invasion and migration, without affecting cell adhesion. Cell migration was inhibited in a variety of cancer cell types and in endothelial cells, with IC50 values of 31-70 microg/ml, much lower than the IC50 values for cytotoxicity of 203-1,217 microg/ml for cancer cells and >4,000 microg/ml for endothelial cells. Fifty percent inhibition of angiogenesis by E. prostrata juice was observed at 200 microg/egg. CONCLUSION: E. prostrata juice inhibited cancer and endothelial cell migration in vitro and also showed in vivo anti-angiogenic activity.     

Oroxylin A,a classical natural product,shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide

BackgroundThere is an obvious relationship among angiogenesis and inflammation. From previous study, we learn that oroxylin A possesses anti-angiogenic activity in vitro and in ovo. It also has an inhibitory effect on inflammation. But whether oroxylin A suppresses the inflammation-induced angiogenesis is still unknown. Our present study focuses on the role of oroxylin A in targeting LPS-induced angiogenesis, inflammatory and related pathways.MethodsThe effects of oroxylin A on angiogenesis were investigated by transwell assay, tube formation assay, rat aortic ring assay and chorioallantoic membrane (CAM) model. Western blotting analysis was used to detect the expression of certain proteins.ResultsWe found that oroxylin A inhibited LPS-induced migration and tube formation of human umbilical vein endothelial cells (HUVECs), as well as microvessel sprouting from rat aotric ring in vitro and the angiogenesis of chicken chorioallantoic membrane (CAM) model in ovo. The results also indicated that oroxylin A could inhibit the expression of LPS acceptor toll-like receptor 4 (TLR4) and the activities of its downstream mitogen-activated protein kinases (MAPKs), including reducing expressions of the phosphorylation of JNK, p38, and ERK. Moreover, oroxylin A prevented NF-κB dimers from translocating to the nucleus.ConclusionsTaken together, oroxylin A can suppress the angiogenesis induced by LPS and it may affect the LPS/TLR4 signaling pathway.     

Apoptosis of human umbilical vein endothelial cells induced by artesunate

Artesunate (ART), a semi-synthetic derivative of artemisinin isolated from the traditional Chinese herb Artemisia annua, is an effective novel antimalarial drug. The present study investigated the apoptotic activity of artesunate in cultured human umbilical vein endothelial cell (HUVEC) by means of nuclear staining, DNA agarose gel electrophoresis, and flow cytometry. The observations also indicated that artesunate induced apoptosis of HUVEC in a concentration-dependent and time-dependent manner. A Western immunoblot analysis showed down-regulation of the bcl-2 protein and up-regulation of the bax protein in the artesunate-treated HUVEC. Ca2+ in cells was evaluated by fluorescent spectrophotometer using Fura 2-AM as probe. These results suggest that artesunate may be a potential apoptosis-inducing agent for endothelial cells.